Cytek Biosciences (CTKB) Operating Expenses (2020 - 2026)

Cytek Biosciences has reported Operating Expenses for 7 years, with the latest figure at $39.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13.05% year-over-year to $39.7 million; the trailing twelve-month figure through Mar 2026 stood at $149.4 million (up 12.34% YoY), and the FY2025 full-year result was $144.8 million, up 10.04% from the prior year.
• Operating Expenses for Q1 2026 stood at $39.7 million, up from $38.5 million in the prior quarter.
• The five-year high for Operating Expenses was $39.7 million in Q1 2026, with the low at $22.5 million in Q1 2022.
• Historically, Operating Expenses has averaged $32.7 million across 5 years, with a median of $33.6 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 68.74% — and 2024, when it declined 8.92%.
• Cytek Biosciences' Operating Expenses stood at $29.3 million in 2022, then gained by 13.3% to $33.2 million in 2023, then slipped by 7.59% to $30.7 million in 2024, then advanced by 25.48% to $38.5 million in 2025, then gained by 3.22% to $39.7 million in 2026.
• The last three Operating Expenses figures came in at $39.7 million (Q1 2026), $38.5 million (Q4 2025), and $36.7 million (Q3 2025), per Business Quant data.